Muszbek N - Search Results

1

Adjusting for treatment crossover in the MAVORIC trial: survival in advanced mycosis fungoides and Sézary syndrome.

Hawkins N, Muszbek N, Evans R, Dequen-O'Byrne P, Jones T, McNamara L. Hawkins N, et al. Among authors: muszbek n. J Comp Eff Res. 2022 Aug;11(11):805-813. doi: 10.2217/cer-2022-0070. Epub 2022 Jun 9. J Comp Eff Res. 2022. PMID: 35678206 Free article. Clinical Trial.

2

Cost-utility analysis of selective internal radiation therapy with Y-90 resin microspheres in hepatocellular carcinoma.

Muszbek N, Remak E, Evans R, Brennan VK, Colaone F, Shergill S, Mullan D, Ross PJ. Muszbek N, et al. Future Oncol. 2021 Mar;17(9):1055-1068. doi: 10.2217/fon-2020-1004. Epub 2020 Nov 23. Future Oncol. 2021. PMID: 33222542

3

Changes in treatment pattern and costs in advanced hepatocellular carcinoma (HCC).

Muszbek N, Evans R, Remak E, Brennan VK, Colaone F, Shergill S, Ross P, Mullan D. Muszbek N, et al. Expert Rev Pharmacoecon Outcomes Res. 2022 Jan;22(1):147-154. doi: 10.1080/14737167.2021.1973892. Epub 2021 Sep 6. Expert Rev Pharmacoecon Outcomes Res. 2022. PMID: 34488517

4

Cost-utility analysis of mogamulizumab in advanced mycosis fungoides and Sézary syndrome cutaneous T-cell lymphoma.

Muszbek N, Remak E, Xin Q, McNamara L, Jones T. Muszbek N, et al. J Comp Eff Res. 2023 Jul;12(7):CER. doi: 10.57264/cer-2023-0028. Epub 2023 Jun 20. J Comp Eff Res. 2023. PMID: 37338181 Free PMC article.

5

Overall survival in the UK in mycosis fungoides or Sézary syndrome cutaneous T-cell lymphoma: comparative effectiveness of mogamulizumab versus current standard of care.

Hawkins N, Muszbek N, Evans R, McNamara L, Jones T. Hawkins N, et al. Among authors: muszbek n. J Comp Eff Res. 2023 Oct;12(10):e230017. doi: 10.57264/cer-2023-0017. Epub 2023 Aug 29. J Comp Eff Res. 2023. PMID: 37642410 Free PMC article.

6

Modelling survival in hepatocellular carcinoma.

Muszbek N, Kreif N, Valderrama A, Benedict A, Ishak J, Ross P. Muszbek N, et al. Curr Med Res Opin. 2012 Jul;28(7):1141-53. doi: 10.1185/03007995.2012.691422. Epub 2012 Jun 26. Curr Med Res Opin. 2012. PMID: 22563794

7

Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada.

Muszbek N, Shah S, Carroll S, McDonald H, Dale P, Maroun J, Knox J. Muszbek N, et al. Curr Med Res Opin. 2008 Dec;24(12):3559-69. doi: 10.1185/03007990802563706. Curr Med Res Opin. 2008. PMID: 19032137 Clinical Trial.

8

Economic evaluation of sorafenib in unresectable hepatocellular carcinoma.

Carr BI, Carroll S, Muszbek N, Gondek K. Carr BI, et al. Among authors: muszbek n. J Gastroenterol Hepatol. 2010 Nov;25(11):1739-46. doi: 10.1111/j.1440-1746.2010.06404.x. J Gastroenterol Hepatol. 2010. PMID: 21039835 Review.

9

The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin's Lymphoma.

Muszbek N, Kadambi A, Lanitis T, Hatswell AJ, Patel D, Wang L, Singer JW, Pettengell R. Muszbek N, et al. Clin Ther. 2016 Mar;38(3):503-15. doi: 10.1016/j.clinthera.2016.01.004. Epub 2016 Feb 5. Clin Ther. 2016. PMID: 26856929 Free article. Clinical Trial.

10

Overview of parametric survival analysis for health-economic applications.

Ishak KJ, Kreif N, Benedict A, Muszbek N. Ishak KJ, et al. Among authors: muszbek n. Pharmacoeconomics. 2013 Aug;31(8):663-75. doi: 10.1007/s40273-013-0064-3. Pharmacoeconomics. 2013. PMID: 23673905 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

24 results

Search Page

Filters